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The T-box transcription factor TBX3 has been implicated in the regulation of embryonic stem cell self-renewal
and cardiogenesis. We have recently discovered that forced TBX3 expression in embryonic stem cells promotes
mesendoderm speciﬁcation directly by activating key lineage speciﬁcation factors and indirectly by enhancing
paracrine NODAL signalling. Interestingly, aberrant TBX3 expression is associated with breast cancer and mela-
noma formation. In other cancers, loss of TBX3 expression is associated with a more aggressive phenotype
e.g. in gastric and cervical cancer. The precise function of TBX3 in pancreatic ductal adenocarcinoma remains
to be determined. In the current study we provide conclusive evidence for TBX3 overexpression in pancreatic
cancer samples as compared to healthy tissue. While proliferation remains unaltered, forced TBX3 expression
strongly increases migration and invasion, but also angiogenesis in vitro and in vivo. Finally, we describe the
TBX3-dependency of cancer stem cells that perpetuate themselves through an autocrine TBX3–ACTIVIN/
NODAL signalling loop to sustain stemness. Thus, TBX3 is a new key player among pluripotency-related genes
driving cancer formation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
TBX3
Pancreas
Pancreatic adenocarcinoma
Development
Cancer stem cells1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most
lethal malignancies in the western world (Jemal et al., 2010). Due to
an increasing incidence it is estimated to be the third leading cause of
cancer-related deaths by 2030 (Rahib et al., 2014).While overall surviv-
al in many solid malignancies has signiﬁcantly improved over the last
decade (Jemal et al., 2010), there has only been a marginal improve-
ment in PDAC despite improved therapies and surgical techniques
(Howlader et al., 2013). At diagnosis, only 15–20% of the patients even
qualify for potentially curative resection. Most patients present with al-
ready locally advanced or metastatic disease, caused by the usually late
diagnosis due tomissing early symptoms and early metastatic spread, adicine I, Ulm University, Albert-
ermann),
. This is an open access article underhallmark of PDAC (Haeno et al., 2012). 5-year survival ranges around 7%
(Jemal et al., 2010; Howlader et al., 2013), and even after surgical resec-
tion and subsequent state-of-the-art adjuvant chemotherapy, the over-
all survival rate does not exceed 20% (Jemal et al., 2010; Haberland et al.,
2010). Regrettably few patients survive longer, but the distinguishing
features that predict long-term survival are not yet fully understood
(Yachida et al., 2012; Russell et al., 2015a). It has been demonstrated
that virtually all cancers including PDAC are highly heterogeneous and
contain a subset of cancer stem cells, tumour cells with features that
distinguish them from the tumour bulk (Al-Hajj et al., 2003; Hermann
et al., 2007; Kim et al., 2005; Li et al., 2007; O'Brien et al., 2007;
Ricci-Vitiani et al., 2007; Singh et al., 2004). These tumour cells can
self-renew, have an exceptionally high tumour-initiating capacity, and
recapitulate the heterogeneity of the parental tumour. Furthermore,
these cells have distinct metabolic (Sancho et al., 2015) and cell cycle
properties, are highly chemoresistant (Ciofﬁ et al., 2015; Mueller et al.,
2009; Hermann et al., 2013; Hermann et al., 2007), and are responsible
for metastatic spread (Hermann et al., 2007). Finally, these cells containthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expression such asNANOGor OCT3/4 and by re-activation of embryonic
pathways such as NODAL/ACTIVIN signalling (Lonardo et al., 2011).
Thus, these pancreatic cancer stem cells share certain stemness features
with bona ﬁde pluripotent embryonic stem cells (Liebau et al., 2014).
The T-box transcription factor 3 (TBX3) belongs to an ancient group
of genes that share a highly conserved DNA binding domain, the T-box
(Muller and Herrmann, 1997; Minguillon and Logan, 2003; Bertolessi et
al., 2015;Weidgang et al., 2016). TBX3 is widely expressed in many tis-
sues, plays a pivotal role during embryonic development, and is tightly
linked to early lineage commitment and the pluripotency of embryonic
stem cells (Kim et al., 2008; Weidgang et al., 2013; Kartikasari et al.,
2013; Russell et al., 2015b; Waghray et al., 2015). Furthermore, TBX3
functions as a transcriptional repressor, is implicated in cell cycle regu-
lation, and in tumour development. TBX3 is overexpressed in human
colorectal (Shan et al., 2015), head andneck (Burgucu et al., 2012), blad-
der (Beukers et al., 2015) and breast cancer (Fan et al., 2004; Yarosh et
al., 2008) aswell as inmelanoma (Peres et al., 2010).Most recently, high
TBX3 expression has been shown to negatively correlate with survival
in a cohort of 80 resected human PDAC samples (Wang et al., 2015),
demonstrating a substantial role of TBX3 in pancreatic cancer. More-
over, TBX3 overexpression was found to be a negative prognostic factor
in colorectal cancer (Shan et al., 2015) and hepatocellular carcinoma
(Renard et al., 2007). Mechanistically, TBX3 is repressed by miR-206
and miR-17-92 to inhibit proliferation but also to decrease the cancer
stem cell population in breast and pancreatic cancer (Ciofﬁ et al.,
2015; Amir et al., 2016), while in certain sarcomas it drives proliferation
via p21 repression. Its expression qualiﬁes as a biomarker to predict
survival (Willmer et al., 2016a;Willmer et al., 2016b). Interestingly, pu-
tative cancer driver mutations in the TBX3 gene cause impaired tran-
scriptional repression in breast cancer (Fischer and Pﬂugfelder, 2015)
and correlate with an invasive lobular carcinoma phenotype (Ciriello
et al., 2015). Therefore, targeting TBX3 itself or its signalling axis may
be of high clinical relevance in the future.
In this study, we aim to close a gap of knowledge determining the
precise function of TBX3 in pancreatic ductal adenocarcinoma. In con-
trast to other cancers, we found TBX3 to be overexpressed in human
PDAC, driving invasion and stemness. Speciﬁcally, TBX3 seems to acti-
vate key genes driving angiogenesis but also sustainingNODAL/ACTIVIN
signalling.
2. Material and methods
2.1. Cell culture and MTT assay
Pancreatic cancer cells were grown in DMEM or RPMI, supplement-
ed with 10% fetal calf serum and 1% Penicillin/Streptomycin. Cells were
grown at 37 °C in a humidiﬁed atmosphere with 5% CO2. Passages used
for experiments ranged from passage 15 to 32.
For cell treatment 10.000 cells/well were seeded in 96 well plates
and grown for 24 h. Following capecitabine (Roche), gemcitabine
(Fresenius Kabi) and cisplatin (Sigma-Aldrich; P4394) were added in
the dosages as referred to in the text. After 24 h, treated cells were
washed with PBS and MTT (Sigma-Aldrich; M2128) was added for 3 h
to allowmetabolization. Finally, DMSOwas added and readout followed
by measuring optical density at 560 nm.
2.2. Lentiviral transduction for stable TBX3 overexpression
HumanTBX3 cDNAwas lentivirally overexpressed using a pLenti6.2/
V5 backbone as described in (Fillmore et al., 2010). pLentiviral particles
were produced according to standard protocols using psPax2 and pMD2
(Addgene; #12260, #12259) as packaging plasmids in LentiX HEK293T
cells (Clontech). Cells were infected directly with LentiX HEK293T
supernatant for 8 h at 37 °C. 24 h later, blasticidine selection was per-
formed at a concentration of 10 μg/ml for 7 days.2.3. Immunohistochemistry of human PDAC samples
Human PDAC tissue microarrays were obtained from a commercial
supplier (BIOMAX US). Immunohistochemical analysis was performed
on the section (Pa1001a using the biotin/streptavidin peroxidase LSAB
kit (Vector Labs). After microwave (20 min) antigen retrieval (citrat
based antigen-retrieval solution pH .0; Dako), an antibody against
TBX3 (Abcam; ab89220) was applied at room temperature, followed
by application of the biotin/streptavidin reagents according to the
manufacturer's instructions. For Ki67 visualization, anti-Ki67 (Abcam;
ab15580, 1:500) antibody was incubated overnight at 4 °C. Tissues
were analyzed and photographed using a Leica stereomicroscope. For
the quantiﬁcation of the immunohistochemistry stainings 10 randomly
selected high power ﬁelds were counted, at 40× magniﬁcation, per
slide. Immunohistochemistry and quantiﬁcation of CAM-derived
tumours were performed similarly. Antibodies used in the CAM were
anti-human Desmin Clone33 (Dako; M0760, 1:100), anti-VEGF
(Abcam; ab1316, 1:100) and anti-Cytokeratin (CAM 5.2 = CK8) (BD
Biosciences; #349205, 1:10), Ki67 (Dako; M7240, 1:80), Vimentin
(Dako; M5020, 1:300), Cytokeratin AE1/AE3 (Dako; M3515, 1:80).
TUNEL staining: In situ cell death detection kit, POD (Roche;
#11684817910).2.4. Immunoﬂuorescence staining
Human pancreatic cancer cells werewashed in PBS and then ﬁxed in
4% Paraformaldehyde (PFA). Sampleswere then treatedwithNH4Cl and
blocked with 0.1% Triton-X-containing BSA before incubation with the
primary antibodies: Mouse antibody against TBX3 (Abcam; ab89220),
dilution 1:50, for 2 h at room temperature and mouse anti-OCT-3/4
(Santa Cruz Biotechnology; sc-9081), dilution 1:10 for 2 h at room tem-
perature. Subsequently, the samples were incubated with ﬂuorescent
labelled secondary antibodies Alexa Fluor® 488 (green), Alexa Fluor®
568 (red), Alexa Fluor® 647 (magenta) (Life-technologies, all diluted
1:500). Nuclei were stained with DAPI (blue) (1:5000). Images were
captured using a Leica TCS SP8-HCS confocal microscope, 63× Plan
Apo Water emersion objectives. Images were acquired in sequential
scan mode and represent single confocal airy sections.2.5. Sphere formation assay
Pancreatic cancer spheres were generated as described previously
(Hermann et al., 2013) and cultured in DMEM-F12 (Invitrogen) supple-
mented with B-27 (Gibco), basic ﬁbroblast growth factor (PeproTech
EC) and heparin (Braun). 15.000 cells/ml were seeded in ultra-low at-
tachment plates (Corning B.V.). Spheres were deﬁned as 3-dimensional
multicellular structures of approximately 40 μm or larger. Sphere for-
mationwas quantiﬁedmanually using a Leica stereomicroscope. Inhibi-
tion of ALK was conducted with SB431542 (ESI BIO).2.6. Flow cytometry
FACSorting was performed as described previously using CD133/
1-PE (Miltenyi Biotech) and EpCAM-APC (BD Bioscience) antibodies
(Hermann et al., 2008). DAPI (eBiosciences) was used to exclude
dead cells. Samples were sorted using a FACS Aria II cell sorter (BD
Bioscience). FACS Apoptosis analysis was performed by using a
FITC Annexin V Apoptosis detection kit with 7-AAD (BioLegend) as
speciﬁed by the manufacturer. For BRDU staining a FITC Mouse Anti-
BrdU antibody (BD Bioscience; #347583 CloneB44) and propidium
iodide were used. The distribution of apoptotic cells and cell cycle
phases were quantiﬁed by BD FACS DIVA software (BD Biosciences)
analysis.
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Transwell migration assays using stably transfected TBX3-OE or
TBX3-SCR BxPC3 and Panc1 cells were performed according to standard
methods as previously described (Eiseler et al., 2012).
2.8. Quantitative real-time PCR and Western blot analysis
Immunoblotting was performed according to standard procedures
as described previously (Kleger et al., 2010; Kleger et al., 2012). Primary
antibodies were as follows: TBX3 antibody (Abcam; ab89220, 1:100)
and β-Actin (Sigma-Aldrich; A2228, 1:1000) .
2.9. CAM assay
CAM assays have been described previously (Azoitei et al., 2011;
Muller et al., 2015). Brieﬂy, shells of fertilised chicken eggswere opened
on day 5 and silicon rings (5 mm in diameter) were applied onto the
chorioallantoic membrane (CAM). On day 8 after fertilisation, 1 × 106
cells (BXPC3 and PANC1, TBX3-OE or scrambled controls) suspended
in 20 μl DMEM/Matrigel (1:1, v/v) were transplanted. After 72 h tu-
mours were harvested and photographed. Tumour size was calculated
after measuring two diameters, n ≥ 4 CAMs per cell line.
2.10. Regulatory genomics analysis
TBX3 ChIP-Seq and control experiments on mouse ES cells
(Waghray et al., 2015) were obtained in Gene Expression Omnibus
(GSE60066). Reads were mapped to mouse mm9 genome using BWA
(Li and Durbin, 2009) and peak calling was performed with MACS
(Zhang et al., 2008) by providing both IP and control signals and a
false discovery rate (FDR) of 0.2 Gene enrichment analysis was per-
formed on TBX3 peaks with GREAT (Zhang et al., 2008) (PMID
20436461). We only report gene sets associated to TGFβ, NODAL and
ACTIVIN, which obtained an adjusted p-value b0.05 with the Binomial
test.
2.11. Statistical analysis
Results for continuous variables are presented as means ± SEM of 3
independent experiments unless stated otherwise. To test for statistical-
ly signiﬁcant differences, nonparametric Mann–Whitney-U testing was
performedusingGraphPad Prism 6 software (GraphPad, SanDiego, CA).
Differences were considered statistically signiﬁcant at either * p b 0.05,
** p b 0.01 or *** p b 0.001.
3. Results
3.1. TBX3 is overexpressed in human PDAC
TBX3 overexpression has been reported for several cancers and usu-
ally predicts poor outcome and more invasive properties (Shan et al.,
2015; Wang et al., 2015). We screened published microarray datasets
for gene expression analyses of PDAC and healthy tissues (Gadaleta et
al., 2011) and were able to conﬁrm an increased expression of TBX3 in
PDAC as compared to either normal tissue adjacent to PDAC or to tissue
from healthy donors (Fig. 1A; http://www.pancreasexpression.org/). To
extend these ﬁndingswe determined TBX3 expression levels via qPCR in
a set of resected human primary tumours and corresponding normal
pancreatic tissue samples. TBX3 was strongly overexpressed in cancer
samples as compared to non-tumour tissue (Fig. 1B). To conﬁrm these
ﬁndings on the protein level, we assessed TBX3 expression via immuno-
histochemistry in tissue microarrays (55 PDAC samples, 17 normal
tissue). While in healthy acinar and ductal tissue TBX3 expression was
very weak or absent, various PDAC samples showed a pronounced nu-
clear TBX3 positivity (Fig. 1C-E and Supp. Fig. 1). Out of 55 tumours,47 were classiﬁed as positive and only 8 as negative for TBX3 (Table
1). Interestingly, the staining was heterogeneous within individual tu-
mours and sometimes revealed only few highly TBX3-positive nuclei,
suggesting a role of TBX3 in a subpopulation of tumour cells. While
we could not observe a direct correlation between tumour stage and
TBX3 expression (Table 1), the high number of TBX3-positive tumors
clearly suggests that TBX3 expression is closely linked to pancreatic
tumour development.
3.2. TBX3 expression has no effect on proliferation or apoptosis in human
pancreatic cancer cells
We measured TBX3 levels in established pancreatic cancer cell lines
(Panc1, BxPC3) and found only low TBX3 expression as demonstrated
via qPCR and immunoblotting (Figs. 2A–C). To determine whether
TBX3 alone is sufﬁcient to promote oncogenic properties in human pan-
creatic cancer, we stably overexpressed TBX3 in these cell lines using a
lentiviral overexpression construct (Figs. 2A–C). Interestingly, overex-
pression of TBX3hadno inﬂuence on the proliferation of pancreatic can-
cer cells as compared to controls resulting in almost identical growth
curves (Fig. 2D and Supp. Fig. 2C). While we could not detect relevant
differences in cell cycle distribution, apoptosis was slightly lower in
TBX3-overexpressing (TBX3-OE) cells as demonstrated by BrdU- and
AnnexinV/7AAD assays (Supp. Fig. 2A,B,D,E). To evaluate the role of
TBX3 during cellular stress, we cultured these cells with the standard
chemotherapeutic agents capecitabine, cisplatin and gemcitabine, as
well as under hypoxia and serumstarvation. However, therewas no sig-
niﬁcant difference in proliferation between TBX3-OE and scrambled
control (TBX3-SCR) cells (Fig. 2G,H and Supp. Fig. 3A–D).
3.3. TBX3 drives migration, invasion and sphere formation in human
pancreatic cancer cells
High proliferation rates, resistance to environmental stress and che-
motherapy are hallmarks of tumour development and aggressiveness.
Further key factors aremigration and invasion of tumour cells, ultimate-
ly resulting in metastasis. Indeed, TBX3 has been shown to mediate
these features in other cancers (Peres et al., 2010; Li et al., 2013;
Mowla et al., 2011). Therefore, we focused on these aspects of tumour
development and evaluated the TBX3-OE cell lines in a series of in
vitro migration and invasion assays. Intriguingly, overexpression of
TBX3 resulted in signiﬁcantly enhanced migration (Fig. 2E and Supp.
Fig. 3E) and invasion (Fig. 2F and Supp. Fig. 3F) in both investigated
pancreatic cancer cell lines.Migration and invasion are usually preceded
by epithelial-to-mesenchymal transition (EMT), which in turn links
stemness and anchorage-independent growth in cancer (Rhim et al.,
2012). In contrast to other tumours (Boyd et al., 2013),we could not ob-
serve EMT features in TBX3-OE cells using qPCR analysis for typical
marker genes (data not shown). In line with our qPCR data, TBX3 over-
expression did not induce EMT as shown by vimentin staining in the ep-
ithelial BxPC3 cells. In contrast, Panc1-derived tumours expressed
vimentin in the cytoplasm of the tumour cells, indicative of amoremes-
enchymal state of these cells. However, overexpression of TBX3 did not
alter vimentin expression in these cells. To more globally assess
increased migration and invasion triggered by TBX3, we used Genomic
Regions Enrichment of Annotations Tool (GREAT) (http://great.
stanford.edu/public/html/index.php) analysis based on published
TBX3-ChIP-sequencing. GREAT associates genomic regions with genes
by deﬁning a ‘regulatory domain’ for each gene in the genome
(Waghray et al., 2015). We have selected out of the signiﬁcantly
enriched terms from TBX3-bound genes, all GO Terms with either
“cytoskeleton”, “focal adhesion”, “migration” and “metastasis” in their
description. This indicates an involvement of TBX3 in both cell migra-
tion and metastasis formation (Fig. 2J).
Finally, we assessed the inﬂuence of TBX3 overexpression on a puta-
tive cancer stemcell population.Weperformed sphere formation assays
Normal Pancreas PDAC
0
20
40
60
80
No
.
of
ca
se
s
TBX3 positive
TBX3 negative
No
.
 
95
6
No
. 9
57
No
. 1
17
7
No
.
 
12
58
No
. 1
10
7
No
.
 
11
44
No
.
 
11
07
0.0
0.5
1.0
1.5
R
el
at
iv
e
ge
ne
e
xp
re
ss
io
n
PDAC Normal pancreas
TBX3
A
B
C
Normal pancreas
PDAC
D
E
TBX3
2
4
6
8
10
Normal 
adjacent PDAC
0
Normal 
donor
R
e
la
tiv
e
m
R
N
A
 le
ve
ls
Fig. 1. Increased TBX3 expression in human pancreatic ductal adenocarcinomas. (A) Tbx3 expression based onmicroarray analysis. Data were taken fromwww.pancreaticexpression.org
and are based on Gadaleta et al. (2011). (B) qRT-PCR analysis of TBX3 expression, showing increased levels in human PDAC samples compared to healthy pancreatic tissue. Data are
represented as relative gene expression of TBX3 and normalized to HMBS. Representative pictures of TBX3 immunohistochemistry in (C) healthy pancreatic tissue and (D) in different
representative PDAC samples. Scale bars: 50 μm. (E) Quantiﬁcation of TBX3 protein expression in a human tissue microarray referring to Table 1. (n ≥ 3 for all experiments).
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higher efﬁciency (Fig. 2I). Thus we conclude that TBX3 expression
does not affect proliferation but drives invasion andmigration, and pro-
motes sphere formation of human pancreatic cancer cells in vitro.
3.4. TBX3 overexpression drives angiogenesis and tumour expansion in vivo
To investigate pro-tumourigenic effects of TBX3 we performed xe-
notransplantation experiments using a chicken chorioallantoic mem-
brane (CAM) assay that faithfully mimics in vivo tumour growth
(Muller et al., 2015; Azoitei et al., 2014; Azoitei et al., 2012; Azoitei et
al., 2010). TBX3 overexpressing BxPC3 and Panc1 cells were
transplanted on the surface of the CAM8 days after fertilization, and xe-
nograft tumour formation was observed, measured, and analysed by
immunohistochemistry (IHC) after 72 h (Fig. 3A). Both macroscopically
and microscopically the tumours generated from TBX3-OE cells were
signiﬁcantly larger than tumours induced by control cells (Fig. 3B–D,F). In line with our in vitro data, Ki67 staining was similar in both
groups (Fig. 3E,G–I). Furthermore, TUNEL-staining did not show signif-
icant differences in apoptosis between TBX3-OE and SCR tumours, albeit
there was a trend towards fewer apoptotic cells in the TBX3 gain of
function groups (Supp. Fig. 4A,B). Of note, TBX3-OE tumours appeared
to be remarkably more invasive than control tumours, with increased
scattered tumour islets, almost penetrating the CAM (Fig. 3B,C; insert).
We then characterized the arising tumours via IHC: Expression of the
ductalmarker CK19was independent of TBX3 expression (Fig. 3H,I). In-
terestingly, visualisation of the exclusively human tumour cell derived
tissue on the CAM by speciﬁc staining for human CK8 illustrates bigger
and more tumour cell clusters indicative for a higher tumour-initiating
capacity of the TBX3-overexpressing cells (Supp. Fig. 4C). Next, we
aimed to investigate EMT in vivo in the context of TBX3 expression.
Vimentin ﬁbres were exclusively deposited in the tumour stroma in
the BxPC3 cells while the Panc1 cells showed baseline positivity for
vimentin indicating a mesenchymal fate in the Panc1 without further
Table 1
Pancreatic cancer cohort (commercial TMA).
Characteristics All % TBX3 pos % TBX3 neg %
55 100 47 85,5 8 14,5
Sex
Male 31 56,4 27 87,1 4 12,9
Female 24 43,6 20 83,3 4 16,7
Age 58,7 58,9 57,8
(Range) (38–80) (38–80) (46–76)
T-Category
T1 - - -
T2 23 41,8 21 44,7 2 25,0
T3 30 54,5 25 53,2 5 62,5
T4 2 3,6 1 2,1 1 12,5
N-Category
NO 44 80,0 36 76,6 8 100,0
N1+ 11 20,0 11 23,4 -
M-Stage
M0 51 92,7 43 91’5 8 100,0
M1 4 7,3 4 8,5 -
Stage grouping
I 21 38,2 19 40,4 2 25,0
II 28 50,9 23 48,9 5 62,5
III 2 3,6 1 3,7 1 25,0
IV 4 7,3 4 14,8 -
Differentiation n=53
Grade 1 8 15,1 7 17,8 1 12,5
Grade 2 30 56,6 26 66,7 4 50,0
Grade 3 15 28,3 12 33,3 3 37,5
TBX3 staining was conﬁrmed as positive when there was at least 1% nuclear labelling
within the cell fraction.
371L. Perkhofer et al. / Stem Cell Research 17 (2016) 367–378impact of TBX3 overexpression in both cell types. No obvious difference
was observed between both groups regarding stroma content
(Fig. 3H,I).
Interestingly, TBX3-overexpressing tumours showed signiﬁcantly
enhanced angiogenesis. Both, increased expression of angiogenesis-as-
sociated genes (FGF2/VEGF-A) as well as increased desmin and VEGF-A
positive structures were detected in TBX3-overexpressing tumours
(Fig. 3 J–M). This observation is further supported by GREAT analysis
in ChIP-seq data. Here the terms “VEGF-signalling” or “Signalling events
mediated by VEGFR1 and VEGFR2“ are among the signiﬁcantly enriched
terms (Fig. 3N). In summary, TBX3 expression enhances tumour growth
and CAM invasion in vivo via increased angiogenesis and most likely by
higher tumour initiation.
3.5. TBX3 promotes a cancer stem cell phenotype in PDAC
In turn, we tried to dissect the underlying mechanism, which
seemed to be independent of proliferation, apoptosis and cellular resis-
tance. To investigate this in more detail we followed up on the observa-
tion that TBX3 overexpression enhances sphere formation and more
tumour cell clusters on the CAM (Fig. 2I; Supp. Fig. 4C). Since this
matches previous data that TBX3 promotes pluripotency of embryonic
stem cells, we hypothesized that TBX3 expression may promote a can-
cer stem cell (CSC) phenotype. Of note, sphere formation assays are
the gold standard to assess the stemness of tumour cells in vitro by
selecting for undifferentiated cells that grow in anchorage-independent
culture conditions with certain growth factors. Due to their inherent
heterogeneity in early passage, primary cancer cells much better reﬂect
the inter-individual differences between tumour patients, and thus
represent a far better model system for the investigation of CSCs than
long-established cell lines (Hermann et al., 2013). Furthermore, we
aimed to investigate the role of endogenous TBX3 in primary tumour
cells without overexpression of TBX3. Thereforewe extended our inves-
tigation to three patient xenograft-derived primary cell lines (Panc354,
Panc185, Panc215) that were generated as described previously
(Rubio-Viqueira and Hidalgo, 2009; Lonardo et al., 2011). Underpinning
the link to CSCs, we found TBX3 to co-localizewith the pluripotency-de-
ﬁning factor OCT3/4 in adherent primary cancer cells (Fig. 4A). CSCs areenriched in the CD133+ subpopulation and in sphere cultures
(Hermann et al., 2007; Lonardo et al., 2011). We therefore sorted the
primary PDAC cell lines for CD133 and could conﬁrm a signiﬁcantly in-
creased mRNA expression of the stemness gene NANOG and TBX3 in
CD133+ cells (Fig. 4B). Furthermore, we were able to show highly pos-
itive TBX3 staining in the CD133+ cells in contrast to a virtual absence in
the CD133− population (Fig. 4C).
Interestingly, both in CD133+ cells as well as in spheres, we ob-
served signiﬁcantly increased TBX3 levels as compared to control cells
(CD133− or adherent cells, respectively; Fig. 4D,E). Increased NANOG
and OCT3/4 expression levels demonstrate elevated stemness in the re-
spective population (Fig. 4D). We have shown previously that TBX3
drives mesendoderm formation via a TBX3 –NODAL–SMAD signalling
axis (Weidgang et al., 2013), and NODAL-signalling has been described
to be essential for cancer stem cell self-renewal (Lonardo et al., 2011;
Lonardo et al., 2012). To shed light on the role of TBX3 expression in
cancer stem cells wemade again use of thementioned ChIP-sequencing
dataset to identify genes directly bound/regulated by TBX3 (Waghray et
al., 2015). Here we identiﬁed strongly enriched GO terms in TBX3-
bound genes that are involved in “NODAL-, TGFβ-, and ACTIVIN-signal-
ling” as demonstrated in Fig. 5A. Encouraged by this global assessment
of pathways driving self-renewal of CSCs (Lonardo et al., 2011), we
wondered whether a core set of genes previously reported to be
enriched in CSCs are directly bound by TBX3. Indeed, NODAL, INHBB
(subunit of ACTIVIN A), SMAD4 and ALK4 show overlapping TBX3 bind-
ingpeakswithDNAse ChIP-sequencing peaks, which is highly indicative
for a direct gene activation (Fig. 5B). To conﬁrm these ﬁndings we
compared expression of these genes in spheres compared to adherent
cells in primary pancreatic cancer cells. Indeed, ACTIVIN A and NODAL
aswell as their downstreameffectors ALK4 and SMAD4were signiﬁcant-
ly increased in spheres (Fig. 5C). Next, we aimed to causally link
ACTIVIN/NODAL signallingwith TBX3 expression and found that stimula-
tion of Panc354 cells with recombinant ACTIVIN resulted in increased
expression of TBX3, NODAL, and ACTIVIN A itself (Fig. 5D). This strongly
suggests that TBX3 is located downstream of the ACTIVIN A signalling
cascade andmight reinforce ACTIVINA signalling directly by its own ex-
pression. To conﬁrm this hypothesis, we generated TBX3-OE primary
pancreatic cancer cells to measure ACTIVIN A levels. As expected, TBX3
overexpression resulted in increased levels of ACTIVIN A, conﬁrming
our hypothesis of increased CSC self-renewal through an autocrine
NODAL/ACTIVIN–TBX3–NODAL/ACTIVIN feedback loop (Fig. 5E). Vice
versa, selective compound inhibition of the Activin Receptor-like Kinase
Receptors 4/5 (ALKs 4/5) with SB431542 signiﬁcantly repressed the ex-
pression of TBX3 and ACTIVIN A (Fig. 5F). Moreover, sphere formation
was greatly reduced by treatment with SB431542 (Fig. 5G,H), which is
well in line with previous reports (Lonardo et al., 2011).
Taken together, we here postulate that TBX3 enhances tumour
growth and aggressiveness via a dual mechanism: Firstly, it increases
migratory and invasive properties in the tumour bulk and secondly it in-
duces a cancer stem cell population by increasing stemness features via
an autocrine NODAL/ACTIVIN–TBX3–NODAL/ACTIVIN axis (Fig. 6).
4. Discussion
The diagnosis of pancreatic ductal adenocarcinoma still means a dis-
mal prognosis for patients. The highly homologous T-box transcription
factor TBX3 is overexpressed in various solid tumours mediating prolif-
eration, EMT, increased invasion/migration, and the ability for cells to
bypass senescence (Shan et al., 2015; Burgucu et al., 2012; Beukers et
al., 2015; Fan et al., 2004; Yarosh et al., 2008). TBX3 is overexpressed
in human PDAC, but its precise role in the development and perpetua-
tion of this tumour remains unclear. However, there is evidence for
TBX3 as a promoter of metastasis (Fillmore et al., 2010) and its expres-
sion has been linked to EMT, as suggested by TBX3-mediated repression
of E-cadherin (Wang et al., 2015; Peres and Prince, 2013). In line with
previous data from Wang et al. (Wang et al., 2015) we conﬁrm TBX3
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Fig. 2. TBX3 promotes migration, invasion and sphere formation capability of human PDAC cell lines. (A–B) TBX3 expression on mRNA and protein levels for scrambled (SCR) and TBX3
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372 L. Perkhofer et al. / Stem Cell Research 17 (2016) 367–378overexpression in PDAC patient samples when compared to normal
pancreatic tissue. For further evaluation of its oncogenic potential we
used well-established and well-characterized human PDAC cell linesand overexpressed TBX3. We could not detect relevant changes in pro-
liferation, which is well in linewith observations in other solid tumours
like melanoma. Interestingly, TBX3 expression even inhibits cell
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376 L. Perkhofer et al. / Stem Cell Research 17 (2016) 367–378proliferation in some tumours (Peres et al., 2010). In contrast to TBX3,
TBX2 is a well-known inducer of proliferation, and is known to be a
downstream target of TBX3 (Muller et al., 2012). One could hypothesize
that the lack of proliferation may result from a direct inhibition of TBX2
as a result of TBX3 overexpression. Furthermore, others have already
shown TBX3 to be a key mediator for TGFβ1 signalling, thus negatively
regulating proliferation and inducing migration and invasion (Li et al.,
2013). On the other hand, we detected a signiﬁcantly increased migra-
tory and invasive capacity in different PDAC cell lines that depended
on TBX3 expression.
In CAM assays as an in vivo platform to study tumorigenic potential,
TBX3 overexpression resulted in a signiﬁcantly increased tumour for-
mation capacity and consecutively larger tumours, which almost pene-
trated the CAM. This is well in line with our in vitro data showing
increased migration and invasion, and is supported by the role of
TBX3 in malignant melanoma, where it drives invasiveness (Peres and
Prince, 2013). Of note, previous reports describe TBX3-dependent
down-regulation of E-cadherin (Boyd et al., 2013), which is recognized
as a crucial step during EMT and subsequent metastatic spread of
tumours (Vanharanta andMassague, 2013).While wemade similar ob-
servations in CAM tumours as suggested by immunohistochemistry and
qPCR, we were unable to detect TBX3-mediated induction of EMT in
vitro. Neither the epithelial BxPC3 nor the more mesenchymal Panc1
cells showed a TBX3-dependent regulation of EMT marker genes. This
might be in line with recent reports showing that EMT is dispensable
for metastasis but induces chemoresistance in pancreatic cancer
(Zheng et al., 2015), and further supports our datasetwhere challenging
cell culture with low serum, hypoxia or chemotherapy showed no
TBX3-dependent effects.
Another explanation for the increased tumour formation might by
the higher intrinsic tumour-initiating capacity of TBX3 overexpressing
cells and a TBX3-related induction of angiogenesis, which we found to
be elevated after TBX3 overexpression. Sincewe have shown previously
that TBX3 is critically involved in the self-renewal and the pluripotency
of induced pluripotent stem cells (iPSCs) (Weidgang et al., 2013; Russell
et al., 2015b), the regulation of a “stemness” phenotype together with
the observation of increased aggressiveness in tumour formation led
us to investigate whether TBX3 serves as a mediator of a cancer stem
cell phenotype in pancreatic cancer. Using sphere formation as an
established surrogate assay for self-renewal in vitro, the overexpression
of TBX3 resulted in signiﬁcantly enhanced sphere formation. Moreover,
TBX3 is highly expressed within spheres. Pancreatic cancer stem cells
are usually enriched by sorting for surface markers such as CD133
(Hermann et al., 2007) or CD44/CD24/EpCAM (Li et al., 2007), or in
sphere cultures that promote the survival and expansion of undifferen-
tiated cells in anchorage-independent conditions. Neither approach
identiﬁes a pure population, and surface markers have been underintense debate since theymay vary considerably on inter-individual dif-
ferences between patients, (chemo-)therapies, culture techniques, and
utilized antibodies (Wicha, 2006). TBX3 is indeed overexpressed in
CD133+ cells and sphere cultures. We therefore proceeded to investi-
gate the functional role of TBX3 in CSCs. We have shown previously
that TBX3 reinforces an autocrine TBX3–NODAL–SMAD2 signalling
loop to mediate mesendodermal differentiation in embryonic stem
cells (Weidgang et al., 2013; Russell et al., 2015b; Weidgang et al.,
2016). The signalling pathways shared between embryonic stem cells
and cancer cells prompted us to use a recent TBX3 ChIP-sequencing
dataset to identify putative self-renewal pathways in CSCs. Not only
did we identify key signalling networks for the self-renewal of pancre-
atic CSCs such as TGFB, NODAL and ACTIVIN signalling, but we also val-
idated these ﬁndings in a set of core genes previously described to be
highly relevant in these processes. Interestingly, the endogenous over-
expression of TBX3 induces NODAL and ACTIVIN, whereas exogenous
treatmentwith recombinant ACTIVIN induces TBX3 expression. This au-
tocrine feedback loop is most likely responsible for the self-renewal of
CSCs. Pharmacological inhibition of key ACTIVIN receptors (ALKs 4/5)
repressed key effects of the TBX3–NODAL–SMAD2 signalling loop such
as gene expression and sphere formation. We have shown previously
that NODAL/ACTIVIN signalling is active in CSCs and that it is critical
for their perpetuation and tumorigenic potential (Lonardo et al.,
2011). Previous studies have already provided evidence for NODAL/
ACTIVIN-induced angiogenesis: (i) inhibition of ALK-4 reduces tu-
mour-angiogenesis in breast cancer cell lines (Siragam et al., 2012)
and (ii) Smad2/Smad3 pathway activation mediated by ALK4 and
ALK5 activates Growth Differentiation Factor 11 (GDF11)–induced mi-
gration and angiogenesis in endothelial progenitor cells (Williams et
al., 2013). This newly postulatedmechanism deserves further investiga-
tion in PDAC, since we could demonstrate a relevant induction of both
VEGF-expression in PDAC cells after TBX3 overexpression and an in-
crease in VEGF and FGF-2 positive vascular structures in the CAM-assay.
Furthermore, we have identiﬁed the tumour stroma, and pancreatic
stellate cells in particular, to be an abundant source of NODAL and
ACTIVIN, thus creating a supportive niche for these highly plastic cells
(Lonardo et al., 2012). Since pancreatic cancers are usually highly
desmoplastic tumours which are characterized by extensive inﬁltration
of stromal cells, paracrine NODAL/ACTIVIN secreted by stellate cells and
TGFβ secreted by CSCs seem to be critical for the perpetuation of CSCs,
and interferencewith this cross-stimulation seems to be highly relevant
for successful therapy (Lonardo et al., 2011; Lonardo et al., 2012). Ac-
cordingly, a miR-19-72 cluster that has been shown to regulate TBX3
expression confers a cancer stem cell phenotype to non-CSCs (Ciofﬁ et
al., 2015).
In summary, we here identify a new TBX3-dependent autocrine
stimulation loop through which CSCs can regulate NODAL/ACTIVIN
377L. Perkhofer et al. / Stem Cell Research 17 (2016) 367–378signalling in the absence of stromal cells. This leads to increased migra-
tory and invasive properties in the tumour, and drives a cancer stem cell
population involving an autocrine positive feedback regulation of the
NODAL/ACTIVIN–TBX3–NODAL/ACTIVIN axis. This establishes TBX3 as
a new key player in cells with cancer stem cell features, and gives a
newmechanistic angle to previous successful approaches for the elimi-
nation of CSCs and subsequently improved therapy against pancreatic
cancer.Conﬂict of interest
None
The following are the supplementary data related to this article
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.08.007.Acknowledgement
We are indebted to Claudia Ruhland and Claudia Längle their excel-
lent technical support. We thank Daniel Hartmann for providing mRNA
from normal pancreas and PDAC samples. This studywas funded by the
Deutsche Forschungsgemeinschaft (DFG, K.L. 2544/1-1 and 1-2), the
Forschungskern SyStaR to A.K., BIU (Böhringer Ingelheim Ulm to A.K.),
the Else-Kröner-Fresenius-Stiftung (2011_A200), a German Cancer Aid
Max Eder Fellowship to P.C.H., a German Cancer Aid Grant to A.K.
(111879), the Fritz-Thyssen Foundation to A.K. (2015-00363) and the
Hector Foundation Cancer Research Fund to P.C.H. A.K. is indebted to
the Baden-Württemberg Stiftung for the ﬁnancial support of this re-
search project by the Eliteprogramme for Postdocs. A.K. is also an Else-
Kröner-Fresenius Memorial Fellow. This work was also supported by
the Interdisciplinary Center for Clinical Research (IZKF Aachen), RWTH
Aachen University Medical School, Aachen, Germany to I.G.C. The Else
Kröner-Forschungskolleg Ulm supports L.P.M.H. receives funding from
the Bausteinprogramm of Ulm University. We thank Dr. Ronan Russell
for generating some of the Tbx3 gain of function cell lines and for
supporting us with the CAM experiments and intellectual input.References
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., 2003. Prospec-
tive identiﬁcation of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100,
3983–3988.
Amir, S., Simion, C., Umeh-Garcia, M., Krig, S., Moss, T., Carraway 3rd, K.L., Sweeney, C.,
2016. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor
microRNA-206 in breast cancer. Br. J. Cancer 114, 1125–1134.
Azoitei, N., Pusapati, G.V., Kleger, A., Moller, P., Kufer, R., Genze, F., Wagner, M., van Lint, J.,
Carmeliet, P., Adler, G., Seufferlein, T., 2010. Protein kinase D2 is a crucial regulator of
tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 59,
1316–1330.
Azoitei, N., Kleger, A., Schoo, N., Thal, D.R., Brunner, C., Pusapati, G.V., Filatova, A., Genze, F.,
Moller, P., Acker, T., Kuefer, R., Van Lint, J., Baust, H., Adler, G., Seufferlein, T., 2011.
Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.
Neuro-Oncology 13, 710–724.
Azoitei, N., Hoffmann, C.M., Ellegast, J.M., Ball, C.R., Obermayer, K., Gossele, U., Koch, B.,
Faber, K., Genze, F., Schrader, M., Kestler, H.A., Dohner, H., Chiosis, G., Glimm, H.,
Frohling, S., Scholl, C., 2012. Targeting of KRASmutant tumors by HSP90 inhibitors in-
volves degradation of STK33. J. Exp. Med. 209, 697–711.
Azoitei, N., Diepold, K., Brunner, C., Rouhi, A., Genze, F., Becher, A., Kestler, H., van Lint, J.,
Chiosis, G., Koren 3rd, J., Frohling, S., Scholl, C., Seufferlein, T., 2014. HSP90 supports
tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res.
74, 7125–7136.
Bertolessi, M., Linta, L., Seufferlein, T., Kleger, A., Liebau, S., 2015. A fresh look on T-box fac-
tor action in early embryogenesis (T-box factors in early development). Stem Cells
Dev. 24, 1833–1851.
Beukers, W., Kandimalla, R., Masius, R.G., Vermeij, M., Kranse, R., van Leenders, G.J.,
Zwarthoff, E.C., 2015. Stratiﬁcation based on methylation of TBX2 and TBX3 into
three molecular grades predicts progression in patients with pTa-bladder cancer.
Mod. Pathol. 28, 515–522.
Boyd, S.C., Mijatov, B., Pupo, G.M., Tran, S.L., Gowrishankar, K., Shaw, H.M., Goding, C.R.,
Scolyer, R.A., Mann, G.J., Kefford, R.F., Rizos, H., Becker, T.M., 2013. Oncogenic B-
RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-
cadherin and enhance melanoma cell invasion. J. Invest. Dermatol. 133, 1269–1277.Burgucu, D., Guney, K., Sahinturk, D., Ozbudak, I.H., Ozel, D., Ozbilim, G., Yavuzer, U., 2012.
Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcino-
ma. BMC Cancer 12, 481.
Ciofﬁ, M., Trabulo, S.M., Sanchez-Ripoll, Y., Miranda-Lorenzo, I., Lonardo, E., Dorado, J., Reis
Vieira, C., Ramirez, J.C., Hidalgo, M., Aicher, A., Hahn, S., Sainz Jr., B., Heeschen, C.,
2015. The miR-17-92 cluster counteracts quiescence and chemoresistance in a dis-
tinct subpopulation of pancreatic cancer stem cells. Gut 64, 1936–1948.
Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H.,
McLellan, M., Yau, C., Kandoth, C., Bowlby, R., Shen, H., Hayat, S., Fieldhouse, R.,
Lester, S.C., Tse, G.M., Factor, R.E., Collins, L.C., Allison, K.H., Chen, Y.Y., Jensen, K.,
Johnson, N.B., Oesterreich, S., Mills, G.B., Cherniack, A.D., Robertson, G., Benz, C.,
Sander, C., Laird, P.W., Hoadley, K.A., King, T.A., Network, T.R., Perou, C.M., 2015. Com-
prehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506–519.
Eiseler, T., Kohler, C., Nimmagadda, S.C., Jamali, A., Funk, N., Joodi, G., Storz, P., Seufferlein,
T., 2012. Protein kinase D1mediates anchorage-dependent and -independent growth
of tumor cells via the zinc ﬁnger transcription factor Snail1. J. Biol. Chem. 287,
32367–32380.
Fan, W., Huang, X., Chen, C., Gray, J., Huang, T., 2004. TBX3 and its isoform TBX3+2a are
functionally distinctive in inhibition of senescence and are overexpressed in a subset
of breast cancer cell lines. Cancer Res. 64, 5132–5139.
Fillmore, C.M., Gupta, P.B., Rudnick, J.A., Caballero, S., Keller, P.J., Lander, E.S., Kuperwasser,
C., 2010. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3
signaling. Proc. Natl. Acad. Sci. U. S. A. 107, 21737–21742.
Fischer, K., Pﬂugfelder, G.O., 2015. Putative breast cancer driver mutations in TBX3 cause
impaired transcriptional repression. Front. Oncol. 5, 244.
Gadaleta, E., Cutts, R.J., Kelly, G.P., Crnogorac-Jurcevic, T., Kocher, H.M., Lemoine, N.R.,
Chelala, C., 2011. A global insight into a cancer transcriptional space using pancreatic
data: importance, ﬁndings and ﬂaws. Nucleic Acids Res. 39, 7900–7907.
Haberland, J., Bertz, J., Wolf, U., Ziese, T., Kurth, B.M., 2010. German cancer statistics 2004.
BMC Cancer 10, 52.
Haeno, H., Gonen,M., Davis, M.B., Herman, J.M., Iacobuzio-Donahue, C.A., Michor, F., 2012.
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggest-
ing optimum treatment strategies. Cell 148, 362–375.
Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J.,
Heeschen, C., 2007. Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (3), 313–323.
Hermann, P.C., Huber, S.L., Heeschen, C., 2008. Metastatic cancer stem cells: a new target
for anti-cancer therapy? Cell Cycle 7, 188–193.
Hermann, P.C., Trabulo, S.M., Sainz Jr., B., Balic, A., Garcia, E., Hahn, S.A., Vandana, M.,
Sahoo, S.K., Tunici, P., Bakker, A., Hidalgo, M., Heeschen, C., 2013. Multimodal treat-
ment eliminates cancer stem cells and leads to long-term survival in primary
human pancreatic cancer tissue xenografts. PLoS ONE 8, e66371.
Howlader, N., Krapcho, M., et al., 2013. SEER Cancer Statistics Review, 1975–2011, Nation-
al Cancer Institute, SEER Web Site,.
Jemal, A., Siegel, R., Xu, J., Ward, E., 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60,
277–300.
Kartikasari, A.E., Zhou, J.X., Kanji, M.S., Chan, D.N., Sinha, A., Grapin-Botton, A., Magnuson,
M.A., Lowry, W.E., Bhushan, A., 2013. The histone demethylase Jmjd3 sequentially as-
sociates with the transcription factors Tbx3 and Eomes to drive endoderm differenti-
ation. EMBO J. 32, 1393–1408.
Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S., Crowley, D.,
Bronson, R.T., Jacks, T., 2005. Identiﬁcation of bronchioalveolar stem cells in normal
lung and lung cancer. Cell 121, 823–835.
Kim, J., Chu, J., Shen, X., Wang, J., Orkin, S.H., 2008. An extended transcriptional network
for pluripotency of embryonic stem cells. Cell 132, 1049–1061.
Kleger, A., Seufferlein, T., Malan, D., Tischendorf, M., Storch, A., Wolheim, A., Latz, S.,
Protze, S., Porzner, M., Proepper, C., Brunner, C., Katz, S.F., Pusapati, G.V., Bullinger,
L., Franz, W.M., Koehntop, R., Giehl, K., Spyrantis, A., Wittekindt, O., Lin, Q., Zenke,
M., Fleischmann, B.K., Wartenberg, M., Wobus, A.M., Boeckers, T.M., Liebau, S., 2010.
Modulation of calcium-activated potassium channels induces cardiogenesis of plurip-
otent stem cells and enrichment of pacemaker-like cells. Circulation 122, 1823–1836.
Kleger, A., Mahaddalkar, P.U., Katz, S.F., Lechel, A., Joo, J.Y., Loya, K., Lin, Q., Hartmann, D.,
Liebau, S., Kraus, J.M., Cantz, T., Kestler, H.A., Zaehres, H., Scholer, H., Rudolph, K.L.,
2012. Increased reprogramming capacity of mouse liver progenitor cells, compared
with differentiated liver cells, requires the BAF complex. Gastroenterology 142,
907–917.
Li, H., Durbin, R., 2009. Fast and accurate short read alignment with Burrows-Wheeler
transform. Bioinformatics 25, 1754–1760.
Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, M.F.,
Simeone, D.M., 2007. Identiﬁcation of pancreatic cancer stem cells. Cancer Res. 67,
1030–1037.
Li, J., Weinberg, M.S., Zerbini, L., Prince, S., 2013. The oncogenic TBX3 is a downstream tar-
get and mediator of the TGF-beta1 signaling pathway. Mol. Biol. Cell 24, 3569–3576.
Liebau, S., Stockmann, M., Illing, A., Seufferlein, T., Kleger, A., 2014. Induced pluripotent
stem cells. A new resource in modern medicine. Internist 55, 460–469.
Lonardo, E., Hermann, P.C., Mueller, M.T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac,
S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J.C., Torres-Ruiz, R., Garcia, E., Hidalgo,
M., Cebrian, D.A., Heuchel, R., Lohr, M., Berger, F., Bartenstein, P., Aicher, A., Heeschen,
C., 2011. Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic
cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9,
433–446.
Lonardo, E., Frias-Aldeguer, J., Hermann, P.C., Heeschen, C., 2012. Pancreatic stellate cells
form a niche for cancer stem cells and promote their self-renewal and invasiveness.
Cell Cycle 11, 1282–1290.
Minguillon, C., Logan, M., 2003. The comparative genomics of T-box genes. Brief. Funct.
Genomic. Proteomic. 2, 224–233.
378 L. Perkhofer et al. / Stem Cell Research 17 (2016) 367–378Mowla, S., Pinnock, R., Leaner, V.D., Goding, C.R., Prince, S., 2011. PMA-induced up-regu-
lation of TBX3 is mediated by AP-1 and contributes to breast cancer cell migration.
Biochem. J. 433, 145–153.
Mueller, M.T., Hermann, P.C., Witthauer, J., Rubio-Viqueira, B., Leicht, S.F., Huber, S.,
Ellwart, J.W., Mustafa, M., Bartenstein, P., D'Haese, J.G., Schoenberg, M.H., Berger, F.,
Jauch, K.W., Hidalgo, M., Heeschen, C., 2009. Combined targeted treatment to elimi-
nate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology
137, 1102–1113.
Muller, C.W., Herrmann, B.G., 1997. Crystallographic structure of the T domain-DNA com-
plex of the Brachyury transcription factor. Nature 389, 884–888.
Muller, M., Stockmann, M., Malan, D., Wolheim, A., Tischendorf, M., Linta, L., Katz, S.F., Lin,
Q., Latz, S., Brunner, C., Wobus, A.M., Zenke, M., Wartenberg, M., Boeckers, T.M., von
Wichert, G., Fleischmann, B.K., Liebau, S., Kleger, A., 2012. Ca2+ activated K chan-
nels-new tools to induce cardiac commitment from pluripotent stem cells in mice
and men. Stem Cell Rev. 8, 720–740.
Muller, M., Schroer, J., Azoitei, N., Eiseler, T., Bergmann, W., Kohntop, R., Lin, Q., Costa, I.G.,
Zenke, M., Genze, F., Weidgang, C., Seufferlein, T., Liebau, S., Kleger, A., 2015. A time
frame permissive for protein kinase D2 activity to direct angiogenesis in mouse em-
bryonic stem cells. Sci. Rep. 5, 11742.
O’Brien, C.A., Pollett, A., Gallinger, S., Dick, J.E., 2007. A human colon cancer cell capable of
initiating tumour growth in immunodeﬁcient mice. Nature 445, 106–110.
Peres, J., Prince, S., 2013. The T-box transcription factor, TBX3, is sufﬁcient to promote
melanoma formation and invasion. Mol. Cancer 12, 117.
Peres, J., Davis, E., Mowla, S., Bennett, D.C., Li, J.A., Wansleben, S., Prince, S., 2010. The high-
ly homologous T-box transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer 1, 272–282.
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., 2014.
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid,
liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921.
Renard, C.A., Labalette, C., Armengol, C., Cougot, D., Wei, Y., Cairo, S., Pineau, P., Neuveut,
C., de Reynies, A., Dejean, A., Perret, C., Buendia, M.A., 2007. Tbx3 is a downstream tar-
get of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival
functions in liver cancer. Cancer Res. 67, 901–910.
Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M.,
Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., Leach, S.D., Stanger, B.Z., 2012. EMT and
dissemination precede pancreatic tumor formation. Cell 148, 349–361.
Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., De Maria, R.,
2007. Identiﬁcation and expansion of human colon-cancer-initiating cells. Nature
445, 111–115.
Rubio-Viqueira, B., Hidalgo, M., 2009. Direct in vivo xenograft tumor model for predicting
chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 85, 217–221.
Russell, R., Perkhofer, L., Liebau, S., Lin, Q., Lechel, A., Feld, F.M., Hessmann, E., Gaedcke, J.,
Guthle, M., Zenke, M., Hartmann, D., von Figura, G., Weissinger, S.E., Rudolph, K.L.,
Moller, P., Lennerz, J.K., Seufferlein, T., Wagner, M., Kleger, A., 2015a. Loss of ATM ac-
celerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat.
Commun. 6, 7677.
Russell, R., Ilg, M., Lin, Q., Wu, G., Lechel, A., Bergmann, W., Eiseler, T., Linta, L., Kumar, P.P.,
Klingenstein, M., Adachi, K., Hohwieler, M., Sakk, O., Raab, S., Moon, A., Zenke, M.,
Seufferlein, T., Schöler, H.R., Illing, A., Liebau, S., Kleger, A., 2015b. A dynamic role of
TBX3 in the pluripotency circuitry. Stem Cell Rep.
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda,
D., Sellers, K., Campos-Olivas, R., Grana, O., Viera, C.R., Yuneva, M., Sainz Jr., B.,
Heeschen, C., 2015. MYC/PGC-1alpha balance determines the metabolic phenotype
and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590–605.Shan, Z.Z., Yan, X.B., Yan, L.L., Tian, Y., Meng, Q.C., Qiu, W.W., Zhang, Z., Jin, Z.M., 2015.
Overexpression of Tbx3 is correlated with epithelial-mesenchymal transition pheno-
type and predicts poor prognosis of colorectal cancer. Am. J. Cancer Res. 5, 344–353.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M.,
Cusimano, M.D., Dirks, P.B., 2004. Identiﬁcation of human brain tumour initiating
cells. Nature 432, 396–401.
Siragam, V., Rutnam, Z.J., Yang, W., Fang, L., Luo, L., Yang, X., Li, M., Deng, Z., Qian, J., Peng,
C., Yang, B.B., 2012. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by
targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget
3, 1370–1385.
Vanharanta, S., Massague, J., 2013. Origins of metastatic traits. Cancer Cell 24, 410–421.
Waghray, A., Saiz, N., Jayaprakash, A.D., Freire, A.G., Papatsenko, D., Pereira, C.F., Lee, D.F.,
Brosh, R., Chang, B., Darr, H., Gingold, J., Kelley, K., Schaniel, C., Hadjantonakis, A.K.,
Lemischka, I.R., 2015. Tbx3 controls Dppa3 levels and exit from pluripotency toward
mesoderm. Stem Cell Rep. 5, 97–110.
Wang, H.C., Meng, Q.C., Shan, Z.Z., Yuan, Z., Huang, X.Y., 2015. Overexpression of Tbx3
predicts poor prognosis of patients with resectable pancreatic carcinoma. Asian Pac.
J. Cancer Prev. 16, 1397–1401.
Weidgang, C.E., Russell, R., Tata, P.R., Kuhl, S.J., Illing, A., Muller, M., Lin, Q., Brunner, C.,
Boeckers, T.M., Bauer, K., Kartikasari, A.E., Guo, Y., Radenz, M., Bernemann, C.,
Weiss, M., Seufferlein, T., Zenke, M., Iacovino, M., Kyba, M., Scholer, H.R., Kuhl, M.,
Liebau, S., Kleger, A., 2013. TBX3 directs cell-fate decision toward mesendoderm.
Stem Cell Rep. 1, 248–265.
Weidgang, C.E., Seufferlein, T., Kleger, A., Mueller, M., 2016. Pluripotency actors on their
lineage move. Stem Cells Int. 2016, 16.
Wicha, M.S., 2006. Cancer stem cells: an old idea–a paradigm shift. Cancer Res. 66,
1883–1890 (discussion 1895–1886).
Williams, G., Zentar, M.P., Gajendra, S., Sonego, M., Doherty, P., Lalli, G., 2013. Transcrip-
tional basis for the inhibition of neural stem cell proliferation and migration by the
TGFbeta-family member GDF11. PLoS ONE 8, e78478.
Willmer, T., Hare, S., Peres, J., Prince, S., 2016a. The T-box transcription factor TBX3 drives
proliferation by direct repression of the p21(WAF1) cyclin-dependent kinase inhibi-
tor. Cell Div 11, 6.
Willmer, T., Cooper, A., Sims, D., Govender, D., Prince, S., 2016b. The T-box transcription
factor 3 is a promising biomarker and a key regulator of the oncogenic phenotype
of a diverse range of sarcoma subtypes. Oncogenesis 5, e199.
Yachida, S., White, C.M., Naito, Y., Zhong, Y., Brosnan, J.A., Macgregor-Das, A.M., Morgan,
R.A., Saunders, T., Laheru, D.A., Herman, J.M., Hruban, R.H., Klein, A.P., Jones, S.,
Velculescu, V., Wolfgang, C.L., Iacobuzio-Donahue, C.A., 2012. Clinical signiﬁcance of
the genetic landscape of pancreatic cancer and implications for identiﬁcation of po-
tential long-term survivors. Clin. Cancer Res. 18, 6339–6347.
Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P.M., Osann, K., Anton-Culver,
H., Huang, T., 2008. TBX3 is overexpressed in breast cancer and represses p14 ARF by
interacting with histone deacetylases. Cancer Res. 68, 693–699.
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C.,
Myers, R.M., Brown, M., Li, W., Liu, X.S., 2008. Model-based analysis of ChIP-Seq
(MACS). Genome Biol. 9, R137.
Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.C., LeBleu, V.S.,
Kalluri, R., 2015. Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature 527, 525–530.
